Kyung Nam Pharm withdraws planned rights offering after SK Securities ends underwriting contract

• Kyung Nam Pharm withdrew its planned shareholder-allotted rights offering, reversing the capital increase decision first announced on May 21, 2026.
• SK Securities terminated the underwriting agreement on Oct. 8 under contract provisions tied to the offering’s regulatory review process.
• Regulatory requests for amendments prolonged the securities filing review, raising risks to the funding timetable and planned use of proceeds.
• The company plans to reassess funding needs and financing options based on cash flow, financial position, project progress, and market conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyung Nam Pharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012000071), on October 12, 2026, and is solely responsible for the information contained therein.